P/E ratio for SurgePays (SURG)
P/E ratio as of April 2024 (TTM): 3.91
According to SurgePays's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 3.90805. At the end of 2022 the company had a P/E ratio of -131.
P/E ratio history for SurgePays from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -131 | 19367.62% |
| 2021 | -0.6739 | -43.8% |
| 2020 | -1.20 | -64.02% |
| 2019 | -3.33 | -91.67% |
| 2018 | -40.0 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.4 | 165.47% | 🇺🇸 USA |
 Novartis NVS | 26.1 | 566.66% | 🇨🇭 Switzerland |
 Stryker Corporation SYK | 49.3 | 1,160.57% | 🇺🇸 USA |
 Cooper Companies COO | 16.0 | 308.18% | 🇺🇸 USA |
 STAAR Surgical STAA | 112 | 2,759.79% | 🇺🇸 USA |
 CONMED CNMD | 34.6 | 785.96% | 🇺🇸 USA |
 Integra LifeSciences IART | 23.2 | 494.61% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.